Carl Zeiss Meditec AG

AFX: XETR (DEU)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€43.00ZdxbgdWcybrtkff

Carl Zeiss Ends Year on Mixed Note; Maintaining Fair Value Estimate

Narrow-moat Carl Zeiss ended its fiscal year with mixed results. Despite strong top-line growth of 15%, operating margins fell slightly. While other medical device manufacturers look primed to rebound after short-term macro headwinds pass, Zeiss seems to have some wind at its back already and less of a runway. We maintain our fair value estimate of EUR 69 per share.

Sponsor Center